Clinical Trial Update: A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating new doses of Xolair (omalizumab) for protection against allergen challenge in asthma patients defined by IgE levels; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 4 | Status: COMPLETED | Results posted: 2011-02-14